vs
Side-by-side financial comparison of Biogen (BIIB) and Owens Corning (OC). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.3B vs $2.1B, roughly 1.1× Owens Corning). Biogen runs the higher net margin — -2.1% vs -13.9%, a 11.8% gap on every dollar of revenue. On growth, Biogen posted the faster year-over-year revenue change (-7.1% vs -24.6%). Biogen produced more free cash flow last quarter ($468.0M vs $333.0M). Over the past eight quarters, Biogen's revenue compounded faster (-0.2% CAGR vs -3.5%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Owens Corning is an American company that develops and produces insulation, roofing, and fiberglass composites and related products. It is the world's largest manufacturer of fiberglass composites. It was formed in 1935 as a partnership between two major American glassworks, Corning Glass Works and Owens-Illinois. The company employs approximately 19,000 people around the world. Owens Corning has been a Fortune 500 company every year since the list was created in 1955. The Pink Panther is the...
BIIB vs OC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.1B |
| Net Profit | $-48.9M | $-298.0M |
| Gross Margin | 78.3% | 23.2% |
| Operating Margin | -2.5% | -10.5% |
| Net Margin | -2.1% | -13.9% |
| Revenue YoY | -7.1% | -24.6% |
| Net Profit YoY | -118.3% | -15.5% |
| EPS (diluted) | $-0.35 | $-3.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $2.1B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.6B | $2.7B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.5B | $2.8B | ||
| Q3 24 | $2.5B | $3.0B | ||
| Q2 24 | $2.5B | $2.8B | ||
| Q1 24 | $2.3B | $2.3B |
| Q4 25 | $-48.9M | $-298.0M | ||
| Q3 25 | $466.5M | $-494.0M | ||
| Q2 25 | $634.8M | $363.0M | ||
| Q1 25 | $240.5M | $-93.0M | ||
| Q4 24 | $266.7M | $-258.0M | ||
| Q3 24 | $388.5M | $321.0M | ||
| Q2 24 | $583.6M | $285.0M | ||
| Q1 24 | $393.4M | $299.0M |
| Q4 25 | 78.3% | 23.2% | ||
| Q3 25 | 73.4% | 28.2% | ||
| Q2 25 | 77.1% | 31.2% | ||
| Q1 25 | 74.1% | 28.7% | ||
| Q4 24 | 76.2% | 28.1% | ||
| Q3 24 | 74.1% | 29.8% | ||
| Q2 24 | 77.8% | 31.1% | ||
| Q1 24 | 76.3% | 29.6% |
| Q4 25 | -2.5% | -10.5% | ||
| Q3 25 | 22.0% | -12.2% | ||
| Q2 25 | 28.1% | 18.4% | ||
| Q1 25 | 12.8% | 16.1% | ||
| Q4 24 | 11.9% | -8.5% | ||
| Q3 24 | 18.3% | 16.7% | ||
| Q2 24 | 28.3% | 16.4% | ||
| Q1 24 | 20.3% | 17.5% |
| Q4 25 | -2.1% | -13.9% | ||
| Q3 25 | 18.4% | -18.4% | ||
| Q2 25 | 24.0% | 13.2% | ||
| Q1 25 | 9.9% | -3.7% | ||
| Q4 24 | 10.9% | -9.1% | ||
| Q3 24 | 15.8% | 10.5% | ||
| Q2 24 | 23.7% | 10.2% | ||
| Q1 24 | 17.2% | 13.0% |
| Q4 25 | $-0.35 | $-3.47 | ||
| Q3 25 | $3.17 | $-5.92 | ||
| Q2 25 | $4.33 | $4.25 | ||
| Q1 25 | $1.64 | $-1.08 | ||
| Q4 24 | $1.82 | $-2.92 | ||
| Q3 24 | $2.66 | $3.65 | ||
| Q2 24 | $4.00 | $3.24 | ||
| Q1 24 | $2.70 | $3.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $345.0M |
| Total DebtLower is stronger | $6.3B | $4.7B |
| Stockholders' EquityBook value | $18.3B | $3.9B |
| Total Assets | $29.4B | $13.0B |
| Debt / EquityLower = less leverage | 0.34× | 1.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $345.0M | ||
| Q3 25 | — | $286.0M | ||
| Q2 25 | — | $230.0M | ||
| Q1 25 | — | $400.0M | ||
| Q4 24 | — | $361.0M | ||
| Q3 24 | — | $499.0M | ||
| Q2 24 | — | $254.0M | ||
| Q1 24 | — | $1.3B |
| Q4 25 | $6.3B | $4.7B | ||
| Q3 25 | $6.3B | $4.7B | ||
| Q2 25 | $6.3B | $5.1B | ||
| Q1 25 | $4.5B | $5.0B | ||
| Q4 24 | $6.3B | $5.1B | ||
| Q3 24 | $4.5B | $5.0B | ||
| Q2 24 | $6.3B | $5.0B | ||
| Q1 24 | $6.3B | $2.6B |
| Q4 25 | $18.3B | $3.9B | ||
| Q3 25 | $18.2B | $4.4B | ||
| Q2 25 | $17.6B | $5.2B | ||
| Q1 25 | $17.0B | $4.9B | ||
| Q4 24 | $16.7B | $5.1B | ||
| Q3 24 | $16.4B | $5.6B | ||
| Q2 24 | $15.9B | $5.5B | ||
| Q1 24 | $15.2B | $5.2B |
| Q4 25 | $29.4B | $13.0B | ||
| Q3 25 | $29.2B | $13.5B | ||
| Q2 25 | $28.3B | $14.5B | ||
| Q1 25 | $28.0B | $14.3B | ||
| Q4 24 | $28.0B | $14.1B | ||
| Q3 24 | $28.3B | $15.1B | ||
| Q2 24 | $26.8B | $15.0B | ||
| Q1 24 | $26.6B | $11.3B |
| Q4 25 | 0.34× | 1.22× | ||
| Q3 25 | 0.35× | 1.06× | ||
| Q2 25 | 0.36× | 0.98× | ||
| Q1 25 | 0.27× | 1.03× | ||
| Q4 24 | 0.38× | 1.01× | ||
| Q3 24 | 0.28× | 0.89× | ||
| Q2 24 | 0.40× | 0.92× | ||
| Q1 24 | 0.41× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $590.0M |
| Free Cash FlowOCF − Capex | $468.0M | $333.0M |
| FCF MarginFCF / Revenue | 20.5% | 15.5% |
| Capex IntensityCapex / Revenue | 1.9% | 12.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $962.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $590.0M | ||
| Q3 25 | $1.3B | $918.0M | ||
| Q2 25 | $160.9M | $327.0M | ||
| Q1 25 | $259.3M | $-49.0M | ||
| Q4 24 | $760.9M | $676.0M | ||
| Q3 24 | $935.6M | $699.0M | ||
| Q2 24 | $625.8M | $493.0M | ||
| Q1 24 | $553.2M | $24.0M |
| Q4 25 | $468.0M | $333.0M | ||
| Q3 25 | $1.2B | $752.0M | ||
| Q2 25 | $134.3M | $129.0M | ||
| Q1 25 | $222.2M | $-252.0M | ||
| Q4 24 | $721.6M | $479.0M | ||
| Q3 24 | $900.6M | $558.0M | ||
| Q2 24 | $592.3M | $336.0M | ||
| Q1 24 | $507.3M | $-128.0M |
| Q4 25 | 20.5% | 15.5% | ||
| Q3 25 | 48.4% | 28.0% | ||
| Q2 25 | 5.1% | 4.7% | ||
| Q1 25 | 9.1% | -10.0% | ||
| Q4 24 | 29.4% | 16.9% | ||
| Q3 24 | 36.5% | 18.3% | ||
| Q2 24 | 24.0% | 12.0% | ||
| Q1 24 | 22.1% | -5.6% |
| Q4 25 | 1.9% | 12.0% | ||
| Q3 25 | 1.8% | 6.2% | ||
| Q2 25 | 1.0% | 7.2% | ||
| Q1 25 | 1.5% | 8.0% | ||
| Q4 24 | 1.6% | 6.9% | ||
| Q3 24 | 1.4% | 4.6% | ||
| Q2 24 | 1.4% | 5.6% | ||
| Q1 24 | 2.0% | 6.6% |
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | 0.90× | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 2.18× | ||
| Q2 24 | 1.07× | 1.73× | ||
| Q1 24 | 1.41× | 0.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
OC
| Insulation | $724.0M | 34% |
| Residential | $625.0M | 29% |
| Doors | $427.0M | 20% |
| Discontinued Operations Disposed Of By Sale | $299.0M | 14% |
| Commercial And Industrial Sector | $101.0M | 5% |
